DE602004032310D1 - Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11 - Google Patents
Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11Info
- Publication number
- DE602004032310D1 DE602004032310D1 DE602004032310T DE602004032310T DE602004032310D1 DE 602004032310 D1 DE602004032310 D1 DE 602004032310D1 DE 602004032310 T DE602004032310 T DE 602004032310T DE 602004032310 T DE602004032310 T DE 602004032310T DE 602004032310 D1 DE602004032310 D1 DE 602004032310D1
- Authority
- DE
- Germany
- Prior art keywords
- cpt
- combination
- combination therapy
- cancer
- antiangiogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0303289A GB0303289D0 (en) | 2003-02-13 | 2003-02-13 | Combination therapy |
| GB0314100A GB0314100D0 (en) | 2003-06-18 | 2003-06-18 | Combination therapy |
| GB0316184A GB0316184D0 (en) | 2003-07-10 | 2003-07-10 | Combination therapy |
| GB0318311A GB0318311D0 (en) | 2003-08-05 | 2003-08-05 | Combination therapy |
| PCT/GB2004/000550 WO2004071397A2 (en) | 2003-02-13 | 2004-02-11 | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004032310D1 true DE602004032310D1 (de) | 2011-06-01 |
Family
ID=32872851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004032310T Expired - Lifetime DE602004032310D1 (de) | 2003-02-13 | 2004-02-11 | Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20060142316A1 (de) |
| EP (1) | EP1592423B1 (de) |
| JP (3) | JP2006517575A (de) |
| KR (2) | KR20110006699A (de) |
| AT (1) | ATE506062T1 (de) |
| AU (1) | AU2004212255B2 (de) |
| CA (1) | CA2514227C (de) |
| CY (1) | CY1111565T1 (de) |
| DE (1) | DE602004032310D1 (de) |
| DK (1) | DK1592423T3 (de) |
| HK (1) | HK1084032A1 (de) |
| IL (1) | IL169702A (de) |
| MX (1) | MXPA05008583A (de) |
| NO (1) | NO331486B1 (de) |
| NZ (1) | NZ541297A (de) |
| PT (1) | PT1592423E (de) |
| SI (1) | SI1592423T1 (de) |
| WO (1) | WO2004071397A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| CA2514227C (en) * | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| KR20120093411A (ko) * | 2003-07-10 | 2012-08-22 | 아스트라제네카 아베 | 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도 |
| CA2569277A1 (en) * | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| NZ568811A (en) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Combination of ZD6474 and pemetrexed for treating cancer and the like |
| EP2066353B1 (de) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Kombination von zd6474 und bevacizumab für die krebstherapie |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72946C2 (uk) * | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| CN1313094C (zh) * | 2002-08-09 | 2007-05-02 | 阿斯利康(瑞典)有限公司 | Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途 |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| CA2514227C (en) * | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| KR20120093411A (ko) * | 2003-07-10 | 2012-08-22 | 아스트라제네카 아베 | 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도 |
| BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| JP4834985B2 (ja) * | 2004-12-10 | 2011-12-14 | 日産自動車株式会社 | 組電池の容量調整装置 |
| NZ568811A (en) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Combination of ZD6474 and pemetrexed for treating cancer and the like |
| EP2066353B1 (de) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Kombination von zd6474 und bevacizumab für die krebstherapie |
-
2004
- 2004-02-11 CA CA2514227A patent/CA2514227C/en not_active Expired - Fee Related
- 2004-02-11 AU AU2004212255A patent/AU2004212255B2/en not_active Ceased
- 2004-02-11 PT PT04710081T patent/PT1592423E/pt unknown
- 2004-02-11 AT AT04710081T patent/ATE506062T1/de active
- 2004-02-11 DE DE602004032310T patent/DE602004032310D1/de not_active Expired - Lifetime
- 2004-02-11 WO PCT/GB2004/000550 patent/WO2004071397A2/en active IP Right Grant
- 2004-02-11 NZ NZ541297A patent/NZ541297A/en not_active IP Right Cessation
- 2004-02-11 MX MXPA05008583A patent/MXPA05008583A/es active IP Right Grant
- 2004-02-11 KR KR1020107027024A patent/KR20110006699A/ko not_active Application Discontinuation
- 2004-02-11 KR KR1020057014913A patent/KR20050100683A/ko active Search and Examination
- 2004-02-11 EP EP04710081A patent/EP1592423B1/de not_active Expired - Lifetime
- 2004-02-11 US US10/543,106 patent/US20060142316A1/en not_active Abandoned
- 2004-02-11 DK DK04710081.3T patent/DK1592423T3/da active
- 2004-02-11 JP JP2006502268A patent/JP2006517575A/ja not_active Withdrawn
- 2004-02-11 SI SI200431690T patent/SI1592423T1/sl unknown
-
2005
- 2005-07-17 IL IL169702A patent/IL169702A/en not_active IP Right Cessation
- 2005-07-27 NO NO20053649A patent/NO331486B1/no not_active IP Right Cessation
-
2006
- 2006-04-11 HK HK06104405.5A patent/HK1084032A1/xx not_active IP Right Cessation
-
2009
- 2009-07-13 US US12/501,599 patent/US20100130520A1/en not_active Abandoned
-
2010
- 2010-10-25 JP JP2010238996A patent/JP5563950B2/ja not_active Expired - Fee Related
- 2010-12-20 US US12/973,271 patent/US20110086870A1/en not_active Abandoned
-
2011
- 2011-06-15 CY CY20111100565T patent/CY1111565T1/el unknown
- 2011-10-27 US US13/282,750 patent/US20120252826A1/en not_active Abandoned
-
2014
- 2014-01-23 JP JP2014010618A patent/JP2014065750A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL169702A0 (en) | 2007-07-04 |
| NO20053649D0 (no) | 2005-07-27 |
| IL169702A (en) | 2014-05-28 |
| KR20050100683A (ko) | 2005-10-19 |
| ATE506062T1 (de) | 2011-05-15 |
| CY1111565T1 (el) | 2015-10-07 |
| CA2514227C (en) | 2011-08-09 |
| WO2004071397A3 (en) | 2004-10-14 |
| JP2014065750A (ja) | 2014-04-17 |
| NZ541297A (en) | 2008-03-28 |
| US20120252826A1 (en) | 2012-10-04 |
| AU2004212255A1 (en) | 2004-08-26 |
| US20060142316A1 (en) | 2006-06-29 |
| JP5563950B2 (ja) | 2014-07-30 |
| SI1592423T1 (sl) | 2011-07-29 |
| AU2004212255B2 (en) | 2007-07-05 |
| JP2011016853A (ja) | 2011-01-27 |
| NO20053649L (no) | 2005-09-12 |
| HK1084032A1 (en) | 2006-07-21 |
| NO331486B1 (no) | 2012-01-16 |
| WO2004071397A2 (en) | 2004-08-26 |
| US20100130520A1 (en) | 2010-05-27 |
| EP1592423A2 (de) | 2005-11-09 |
| JP2006517575A (ja) | 2006-07-27 |
| PT1592423E (pt) | 2011-06-16 |
| MXPA05008583A (es) | 2005-11-04 |
| US20110086870A1 (en) | 2011-04-14 |
| EP1592423B1 (de) | 2011-04-20 |
| KR20110006699A (ko) | 2011-01-20 |
| CA2514227A1 (en) | 2004-08-26 |
| DK1592423T3 (da) | 2011-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053649L (no) | Kombinasjonsterapi | |
| HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
| ATE500832T1 (de) | Kombination von zd6474 und pemetrexed | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
| MX2007005356A (es) | Terapia de combinacion que comprende zd6474 y un antiadrogenico. | |
| HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| NO20064755L (no) | Kombinasjonsterapi | |
| NO20056171L (no) | Kombinasjonsterapi | |
| NO20064754L (no) | Kombinasjonsterapi | |
| MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. |